ZOLL Selected to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange

CHELMSFORD, Mass.--(BUSINESS WIRE)--Oct 3, 2022--

ZOLL, an Asahi Kasei company, has been selected to exhibit SuperSaturated Oxygen (SSO 2 ) Therapy, which delivers high levels of dissolved oxygen directly to the heart following severe heart attack, at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven health care performance improvement company, will hold the Exchange on October 17 in Dallas.

The annual Innovative Technology Exchange offers selected suppliers the unique opportunity to demonstrate their technologies to supply chain and clinical leaders from Vizient’s member hospitals and subject matter experts who serve on their supply councils. Each technology will showcase how it improves clinical outcomes, enhances safety or drives incremental improvements to health care delivery or business models.

ZOLL’s TherOx SSO 2 Therapy is the first FDA-approved, catheter-based therapy to safely and effectively reduce infarct size (damage to heart muscle) in randomized control trials. 1 SSO 2 is used immediately after stenting is performed for left anterior descending (LAD) ST-segment elevation (STEMI) heart attacks — the most severe type — and within six hours of symptom onset. SSO 2 delivers high levels of dissolved oxygen directly to the heart to recover damaged tissue. Data have shown that SSO 2 is associated with lower rates of heart failure and death within one year. 2

“SSO 2 Therapy represents the first major milestone in STEMI care in almost 20 years,” said Christopher Barnabas, President of ZOLL Circulation. “We feel honored to have been included in this important event and look forward to showcasing SSO 2 Therapy as the next step in improving care and outcomes for STEMI patients.”

“The Exchange is an exciting part of the Vizient Innovative Technology Program, which results in Innovative Technology contract awards for the qualified products. This signals health care providers of a product’s unique qualities,” said Kelly Flaharty, senior director of contract services, Vizient. “With only a select number of suppliers invited to demonstrate their products, it’s an honor to be invited.”

The annual Innovative Technology Exchange is part of Vizient’s Innovative Technology Program that includes product review of supplier-submitted technologies by member-led councils and task forces. Since 2003, Vizient has reviewed over 1,600 product submissions as part of its Innovative Technology Program.

About ZOLL

ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, visit www.zoll.com.

___________________________

View source version on businesswire.com:https://www.businesswire.com/news/home/20221003005061/en/

CONTACT: Media contact:

Matt Hogan

ZOLL

978-805-6561

media@zoll.com

KEYWORD: TEXAS MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: CARDIOLOGY DATA MANAGEMENT TECHNOLOGY MANUFACTURING OTHER HEALTH HEALTH GENERAL HEALTH OTHER TECHNOLOGY MEDICAL DEVICES OTHER MANUFACTURING HARDWARE

SOURCE: ZOLL

Copyright Business Wire 2022.